Pharmacologically active strong acid solutions

Abstract

A composition and therapeutic methods therefore for pharmacologically strong acid solutions comprising a mixture of strong and weak acids.

1 . A pharmaceutical composition comprising a mixture of three strong acids and three weak acids.  
     
     
         2 . The composition of  claim 1  wherein at least one (1) of the weak acids is hydrofluoric acid.  
     
     
         3 . The composition of  claim 1  wherein the acids are selected from the group consisting of sulfuric, hydrochloric, oxalic, phosphoric, citric and hydrofluoric acids.  
     
     
         4 . The composition of  claim 1  wherein the acids are present in the following concentrations by weight:  
       
         
           
                 
                 
                 
               
                     
                     
                 
                     
                     
                 
                     
                   HCl 
                   3-25% 
                 
                     
                   H 2 C 2 O 4   
                   0.1-10%   
                 
                     
                   H 3 PO 4   
                   3-10% 
                 
                     
                   HF 
                   1-30% 
                 
                     
                     
                 
                     
                     
                 
             
                
                
               
               
                
                
                
                
                
                
               
            
           
         
       
     
     
         5 . The composition of  claim 1  wherein the acids are present in the following concentrations by weight:  
       
         
           
                 
                 
                 
               
                     
                     
                 
                     
                     
                 
                     
                   HCl 
                    5-15% 
                 
                     
                   H 2 C 2 O 4   
                   0.15-2%   
                 
                     
                   H 3 PO 4   
                   2-7% 
                 
                     
                   HF 
                   2-7% 
                 
                     
                     
                 
                     
                     
                 
             
                
                
               
               
                
                
                
                
                
                
               
            
           
         
       
     
     
         6 . The composition of  claim 1  wherein the acids are present in the following approximate concentrations by weight:  
       
         
           
                 
                 
                 
               
                     
                     
                 
                     
                     
                 
                     
                   HCl 
                   11% 
                 
                     
                   H 2 C 2 O 4   
                   0.3%  
                 
                     
                   H 3 PO 4   
                    6% 
                 
                     
                   H 2 SO 4   
                   16% 
                 
                     
                   HF 
                    5% 
                 
                     
                   H 8 C 6 O 7   
                   0.3%  
                 
                     
                     
                 
                     
                     
                 
             
                
                
               
               
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         7 . The composition of  claim 1  further comprising glycerin.  
     
     
         8 . The composition of claim one wherein the composition has a pH of below 1.  
     
     
         9 . A method of treating a patient suffering from at least on of the following conditions selected from the group of: cancer related pain, cancer, high blood pressure, and infectious disease; comprising the internal administration of a composition comprising a mixture of HCl, H 2 SO 4 , H 2 C 2 O 4 , H 3 PO 4 , H 8 C 6 O 7 , and HF.  
     
     
         10 . The method of  claim 9  wherein the patient is premedicated with a pharmaceutical product selected from the group consisting of: H 2  blockers, proton pump inhibitors, anti-inflammatories, antiemetics, and combinations thereof.  
     
     
         11 . The method of  claim 9  wherein the cancer is selected from the group consisting of: endocrine, brain, ovarian, breast, venereal, prostate, skin, bone, lung, liver, stomach, colon, head and neck, blood or lymph, bone marrow, digestive tract, combinations thereof, chemotherapy resistant cancer and radiation resistant cancer.  
     
     
         12 . The method of  claim 11  wherein the cancer is injected with the composition.  
     
     
         13 . The method of  claim 9  in which cancer cells are selectively destroyed.  
     
     
         14 . The method of  claim 9  wherein tumor markers are reduced.  
     
     
         15 . The method of  claim 9  wherein the chromatin is destroyed in the cancer cells.  
     
     
         16 . The method of  claim 9  wherein the infectious disease is selected from the group consisting of: bacteria, viruses and fungi.  
     
     
         17 . The method of  claim 9  wherein the composition has a pH of below 1.  
     
     
         18 . The method of  claim 9  wherein the composition is administered through a method selected from the group consisting of: orally, intravenously, intramuscularly, intraperitoneally sub-cutaneously, rectally, intra-urethrally, topically, intravesically, intravaginally, and combinations thereof.  
     
     
         19 . A method of treating cancer comprising the administration, to a patient in need thereof, an effective amount of a an acid buffer comprising:  
       
         
           
                 
                 
                 
               
                     
                     
                 
                     
                     
                 
                     
                   HCl 
                    5-15% 
                 
                     
                   H 2 C 2 O 4   
                   0.15-2%   
                 
                     
                   H 3 PO 4   
                   2-7% 
                 
                     
                   HF 
                   2-7% 
                 
                     
                     
                 
                     
                     
                 
             
                
                
               
               
                
                
                
                
                
                
               
            
           
         
       
       wherein the pH is of the undiluted buffer is below 1.  
     
     
         20 . The method of  claim 19  wherein the buffer is diluted in a pharmacologically acceptable solvent.